Canadian Nuclear Safety Commission | Commission canadienne de sûreté nucléaire

CMD 21-H100.8

File/dossier : 6.01.07
Date : 2021-05-26
e-Docs pdf : 6571839

Written submission from Pediatric Oncology Group of Ontario

Mémoire de Pediatric Oncology Group of Ontario

In the Matter of

À l'égard de

Application to allow the production of lutetium-177(Lu-177) at the Bruce Nuclear Generating Station (NGS)

Demande de modification de permis visant à permettre la production de lutécium 177 à la centrale nucléaire de Bruce

Public Hearing - Hearing in writing based on written submissions

Audience Publique - Audience fondée sur des mémoires

June 2021

Juin 2021

Canada

POGO
PEDIATRIC ONCOLOGY GROUP OF ONTARIO

FOR KIDS WITH CANCER
FOR NOW, FOR LIFE.

May 25, 2021

Tribunal Officer, Secretariat
Canadian Nuclear Safety Commission
280 Slater Street
P.O. Box 1046, Station B
Ottawa, Ontario K1P 5S9
Email: cnsc.interventions.ccsn@canada.ca

Re: Bruce Power Licence Amendment Application (June 25, 2021 Hearing in Writing)

Dear President and Commission Members,

The Pediatric Oncology Group of Ontario (POGO) works to ensure that everyone affected by childhood cancer has access to the best care and support. For more than 30 years, we have worked with partners like Bruce Power to achieve an excellent childhood cancer care system for children, youth, their families, survivors and healthcare teams in Ontario and beyond.

As POGO Medical Director and Chair of Childhood Cancer Control, and in my clinical and research role as a pediatric radiation oncologist, I understand the importance of visionary leadership in creating a state-of-the-art, evidence-based cancer delivery system for children with malignant disease.

Bruce Power has a proud legacy of supplying life-saving medical isotopes across the globe to keep medical equipment sterilized and assist in fighting disease. Its power reactors have been used to produce longer lived radioactive isotopes such as cobalt-60. With its partner IsoGen, Bruce Power has begun work on a novel, made-in-Ontario, Isotope Production System (IPS) and, in November 2020, submitted a licence amendment application to produce Lutetium-177, which is currently used to treat neuroendocrine tumours and has additional applications for prostate and breast cancer treatments.

POGO supports the development of improved domestic isotope production, and believes these isotopes will be increasingly important in cancer treatment. Specifically,

- advances in radiopharmacy have made medical isotopes an increasingly important component in the management of cancer patients, including children;

- these isotopes are emerging as a critical component not only in the necessary imaging tests done for cancer patients, but increasingly as a form of treatment; and
- recent experience with COVID vaccine access has illustrated the importance of domestic manufacturing capacity in ensuring that Canadians have optimal access to medically necessary components of treatment.

In so much as Bruce Power will continue to build on its long-standing track record with the successful granting of this licence, POGO trusts that Bruce Power will continue to transform the landscape of cancer treatment in Ontario.

Sincerely,



David Hodgson, MD, MPH, FRCPC
POGO Medical Director & Chair in Childhood Cancer Control
Professor, Department of Radiation Oncology & Institute of Health Policy, Management & Evaluation University of Toronto